KDR and non-small cell lung carcinoma: VEGF and VEGFR are the most important regulatory factors for tumor angiogenesis, and by specifically inhibiting their activity, tumor angiogenesis can be reduced so as to promote tumor necrosis.[8] As a broad-spectrum anti-VEGF monoclonal antibody, bevacizumab has been proven safe and effective in non-squamous NSCLC.